GH Research PLC (NASDAQ:GHRS) Given Consensus Rating of “Buy” by Analysts

GH Research PLC (NASDAQ:GHRS) has earned a consensus recommendation of “Buy” from the seven brokerages that are covering the stock, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $30.86.

Several equities research analysts have recently commented on GHRS shares. Stifel Nicolaus upped their target price on GH Research from $18.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, February 27th. Cantor Fitzgerald began coverage on shares of GH Research in a research note on Thursday, February 13th. They set an “overweight” rating and a $14.00 price objective for the company. Royal Bank of Canada started coverage on shares of GH Research in a research report on Friday, March 7th. They issued an “outperform” rating and a $31.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of GH Research in a research report on Monday, January 27th. Finally, Guggenheim assumed coverage on shares of GH Research in a research report on Thursday, March 13th. They set a “buy” rating and a $32.00 price objective on the stock.

Institutional Trading of GH Research

Institutional investors have recently made changes to their positions in the stock. RA Capital Management L.P. lifted its position in GH Research by 1.3% in the 3rd quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company’s stock worth $44,734,000 after buying an additional 85,000 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of GH Research by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 72,513 shares of the company’s stock worth $508,000 after acquiring an additional 3,092 shares during the last quarter. Diadema Partners LP purchased a new stake in shares of GH Research during the fourth quarter worth $711,000. Lynx1 Capital Management LP boosted its position in GH Research by 15.8% during the fourth quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock valued at $34,013,000 after purchasing an additional 663,100 shares during the last quarter. Finally, Northern Trust Corp grew its stake in GH Research by 26.8% in the fourth quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock valued at $286,000 after purchasing an additional 8,641 shares in the last quarter. 56.90% of the stock is currently owned by institutional investors and hedge funds.

GH Research Price Performance

Shares of GHRS opened at $9.32 on Tuesday. GH Research has a 12-month low of $6.00 and a 12-month high of $20.50. The stock has a market capitalization of $484.90 million, a P/E ratio of -11.80 and a beta of 0.84. The firm’s 50 day moving average is $11.93 and its 200-day moving average is $9.44.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.06. As a group, equities research analysts forecast that GH Research will post -0.8 EPS for the current fiscal year.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).